Notification under Listing Rule 4.3D

Summary by 6ix AI

The adjustments involve an increase in research and development expenses and trade payables due to a reconciliation with a contract research organization after the early termination of a clinical trial. The filing also confirms that the total amount agreed with the CRO is within previously disclosed forecasts for trial close-out costs.

Written by 6ix AI from the company’s filing. How 6ix writes summaries